Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Cancer Institute of New Jersey National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00176540 |
RATIONALE: Dextromethorphan may help relieve fatigue in patients with cancer.
PURPOSE: This clinical trial is studying how well dextromethorphan works in treating patients with fatigue caused by cancer.
Condition | Intervention |
---|---|
Fatigue Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific |
Drug: dextromethorphan hydrobromide |
Study Type: | Interventional |
Study Design: | Supportive Care, Open Label |
Official Title: | A Pilot Trial to Evaluate the Effects of Dextromethorphan in Patients Suffering From Cancer-Related Fatigue |
Estimated Enrollment: | 30 |
Study Start Date: | March 2004 |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter, open-label, pilot study.
Patients receive oral dextromethorphan hydrobromide 3 times a day on days 1-7. Treatment repeats weekly for up to 3 weeks in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Ages Eligible for Study: | 12 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of malignancy
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, New Jersey | |
Cancer Institute of New Jersey at Hamilton | |
Hamilton, New Jersey, United States, 08690 | |
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School | |
New Brunswick, New Jersey, United States, 08903 |
Principal Investigator: | Susan Goodin, PharmD | Cancer Institute of New Jersey |
Study ID Numbers: | CDR0000539650, CINJ-5017v2, CINJ-4598, CINJ-NJ11005 |
Study First Received: | September 12, 2005 |
Last Updated: | August 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00176540 |
Health Authority: | United States: Federal Government |
unspecified adult solid tumor, protocol specific unspecified childhood solid tumor, protocol specific fatigue |
Naphazoline Oxymetazoline Excitatory Amino Acids Signs and Symptoms Fatigue |
Guaifenesin Phenylephrine Dextromethorphan Phenylpropanolamine |
Respiratory System Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs |
Excitatory Amino Acid Agents Antitussive Agents Central Nervous System Agents Pharmacologic Actions Excitatory Amino Acid Antagonists |